A Multicenter Adaptive Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Coronavirus Infection, Unspecified Site
  • Age: Between 18 - 110 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects who are admitted to a hospital with symptoms suggestive of COVID-19 infection.
    2. Subjects (or legally authorized representatives) able to provide written informed consent prior to initiation of any study procedures
    3. Subjects who understand and agree to comply with planned study procedures.
    4. Subjects who agree to the collection of oropharyngeal (OP) swabs.
    5. Subjects =18 years of age at time of enrollment.
    6. Subjects who have laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay in any specimen collected <72 hours prior to randomization
    7. Subjects with illness of any duration, and at least one of the following:
      • Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
      • Clinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, OR
      • Requiring supplemental oxygen, OR
      • Requiring mechanical ventilation
    8. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception for the duration of the study
    9. Subjects agree to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29

You may not be eligible for this study if the following are true:

    1. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours
    2. Meets criteria for ordinal scale category 6 or 7 at the time of screening
    3. Subjects have a positive test for influenza virus during this current hospital admission
    4. Subjects with an estimated glomerular filtration rate (eGFR) < 30 mL/min
    5. ALT or AST > 5 times the upper limits of normal
    6. Total white cell blood cell count (WBC) <1500 cells/µL
    7. Platelet count <50,000/µL
    8. History of chronic liver disease
    9. Pregnancy or breast feeding
    10. Allergy to any study medication
    11. Has chronic or acute medical condition or is taking a medication that cannot be discontinued at enrollment, that in the judgement of the PI, places them at unacceptable risk for a poor clinical outcome if they were to participate in the study
    12. Received three or more doses of remdesivir, including the loading dose, outside of the study for COVID-19
    13. Received convalescent plasma or intravenous immunoglobulin [IVIg]) for the treatment of COVID-19
    14. Prior enrollment in ACTT-3

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.